Tranexamic Acid News and Research

RSS

Cryoprecipitate plus tranexamic acid boost war injury survival

Administration of cryoprecipitate and tranexamic acid significantly improves the likelihood of survival among seriously injured patients requiring packed red blood cells, suggest results from MATTERS II.

21 Nov 2012

Tranexamic acid: an interview with Prof Ian Roberts

Tranexamic acid is a medicine that reduces blood clot breakdown. In this way it helps in patients with bleeding.

19 Sep 2012

Tranexamic acid lifesaving across the board

Tranexamic acid confers survival benefits in trauma patients irrespective of their baseline mortality risk, shows a prespecified analysis of CRASH-2.

18 Sep 2012

Comic created to help busy medical staff on the benefits of tranexamic acid

Researchers at the London School of Hygiene & Tropical Medicine have created a comic influenced by the Japanese manga style to help busy medical staff who treat patients suffering from bleeding.

12 Sep 2012

Predictors of early death after traumatic bleeding uncovered

The strongest predictors of early death after traumatic postinjury bleeding are Glasgow coma score, age, and systolic blood pressure, report researchers.

4 Sep 2012

Tranexamic acid reduces bleeding in off-pump coronary bypass surgery

Patients undergoing off-pump coronary artery bypass grafting who are given a tranexamic acid infusion show a modest reduction in postoperative bleeding and blood transfusion relative to their placebo-treated peers, a clinical trial shows.

15 Aug 2012

Knee surgery blood loss reduced with single tranexamic acid dose

A single intraoperative dose of tranexamic acid is effective at reducing blood loss in patients undergoing minimally invasive total knee arthroplasty, research suggests.

20 Jul 2012

APP expands portfolio of injectable critical care products

APP Pharmaceuticals, LLC, a Fresenius Kabi Company, today announced it has acquired three products from Nexus Pharmaceuticals, Inc.

24 May 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

FDA approves Mylan's Tranexamic Acid Injection ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials.

3 Dec 2011

Ferring reports on FDA approval of labeling supplement for EUFLEXXA to treat knee osteoarthritis

On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.

22 Oct 2011

Tranexamic acid effective for patients with head injury

New research has suggested that tranexamic acid has the potential to prevent people dying from head injuries.

1 Jul 2011

Study measures cost-effectiveness of trauma drug published in PLoS One

How much would you pay for an extra year of healthy life? The cost of filling up your car at the petrol pumps? Researchers at the London School of Hygiene & Tropical Medicine have found that a year of life could be saved for around the price of filling up the tank of an average family car in the UK - which is a fitting comparison bearing in mind that most of the patients who will benefit from this cheap life-saving drug have been hit by cars.

4 May 2011

'Consent rituals' cause life-threatening delays

Current rules requiring researchers to obtain consent for patients to take part in clinical trials in emergency situations are causing life-threatening delays to treatment, experts have argued.

25 Mar 2011

Rapid treatment within an hour of injury dramatically cuts bleeding deaths in injured patients

An hour can make the difference between life and death when using tranexamic acid to treat injured patients with severe bleeding, a study by researchers at the London School of Hygiene & Tropical Medicine suggests.

24 Mar 2011

Omeros receives exclusive license for new series of antifibrinolytic agents

Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents. These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding.

6 Jan 2011

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

Early administration of TXA reduces death from bleeding without increase in complications: Study

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.

12 Aug 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010